Article

Oral uveitis agent set for phase III trial

Patient enrollment has been completed for a phase III clinical trial of oral voclosporin (Luveniq, Lux Biosciences) for the treatment of non-infectious uveitis.

Jersey City, NJ-Patient enrollment has been completed for a phase III clinical trial of oral voclosporin (Luveniq, Lux Biosciences) for the treatment of non-infectious uveitis.

Oral voclosporin will be evaluated in a 6-month, randomized, multicenter, double-masked, controlled trial to evaluate its efficacy and safety for the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye. A total of 155 patients will be enrolled at 56 sites across North America, Europe, and Brazil. The primary endpoint of the trial will be the change from baseline in vitreous haze at 12 weeks or at the time of treatment failure, if earlier.

Lux Biosciences anticipates data from the trial will be available early in the first quarter of 2013. The company also anticipates that the results from this trial, if positive, will address the FDA’s request for additional clinical information as part of the complete response letter regarding the New Drug Application (NDA) for oral voclosporin issued in August 2010, and that it also will support a resubmission of the NDA under priority review early in 2013.

Lux Biosciences additionally expects the trial results, if positive, to support a regulatory filing to the European Medicines Agency.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.